Rufinamide
- CAS No.
- 106308-44-5
- Chemical Name:
- Rufinamide
- Synonyms
- 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide;E 2080;RUF 331;CS-1133;Inovelon;CGP 33101;Rufinamide;Rufinamide>Rufinamide, >=99%;Rufinamide(E 2080
- CBNumber:
- CB5972298
- Molecular Formula:
- C10H8F2N4O
- Molecular Weight:
- 238.19
- MOL File:
- 106308-44-5.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/29 17:07:33
| Melting point | 232-234?C |
|---|---|
| Boiling point | 473.8±55.0 °C(Predicted) |
| Density | 1.52±0.1 g/cm3(Predicted) |
| Flash point | 2℃ |
| storage temp. | -20°C |
| solubility | DMSO: soluble9mg/mL |
| pka | 14.37±0.50(Predicted) |
| form | powder |
| color | white |
| Merck | 14,8293 |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H336-H351-H361fd |
| Precautionary statements | P201-P202-P261-P271-P280-P308+P313 |
| Hazard Codes | F,T |
| Risk Statements | 11-23/24/25-39/23/24/25-48-41-38-28 |
| Safety Statements | 7-16-36/37-45-36/37/39-28-26-24/25 |
| RIDADR | UN 1648 3 / PGII |
| WGK Germany | 3 |
| HS Code | 29339900 |
Rufinamide price More Price(7)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | R8404 | Rufinamide ≥98% (HPLC), powder | 106308-44-5 | 10MG | ₹13780.23 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | R8404 | Rufinamide ≥98% (HPLC), powder | 106308-44-5 | 50MG | ₹61962.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | R-023 | Rufinamide solution 1.0?mg/mL in acetonitrile: water (9:1), certified reference material, Cerilliant? | 106308-44-5 | 1ML | ₹18300.8 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1625 | Rufinamide Pharmaceutical Secondary Standard; Certified Reference Material | 106308-44-5 | 500MG | ₹16540.6 | 2022-06-14 | Buy |
| TCI Chemicals (India) | R0143 | Rufinamide | 106308-44-5 | 25MG | ₹2300 | 2022-05-26 | Buy |
Rufinamide Chemical Properties,Uses,Production
Description
Approximately 2.5 million people worldwide are afflicted with epilepsy, a devastating neurological disorder diagnosed by the tendency toward recurrent, unprovoked seizures, often of unknown etiology. Rufinamide has been launched primarily as adjunctive therapy of LGS. Its proposed mechanism of action involves the limitation of firing of sodium-dependent action potentials. The ultimate result is membrane stabilization. Since it does not exhibit measurable binding to monoamine, acetylcholine, histamine, glycine, AMPA/kainate, NMDA, or GABA receptors or systems, these receptor-mediated pathways are not anticipated to be involved in the exertion of rufinamide’s effects. Rufinamide displayed efficacy in several electrical and chemical animal seizure models.
Chemical Properties
White Solid
Uses
Labelled Rufinamide (R701552). Antiepileptic triazole derivative which decreases firing by neurons at sodium channels. Anticonvulsant.
General Description
An antiepileptic drug and anticonvulsant, Rufinamide is approved for the treatment of partial seizures associated with Lennox-Gastaut syndrome in adults and children 4 years and older. Rufinamide is marketed as Banzel® in the US and Inovelon® in the EU.
Biological Activity
Board spectrum anticonvulsant. Prolongs the inactivation of sodium channels and limits the frequency of action potential firing in cultured and acutely isolated neurons. Displays anticonvulsive activity in a range of animal seizure models.
Side effects
Rufinamide was well tolerated with the most common adverse events including fatigue, somnolence, tremors, mild-to-moderate dizziness, nausea, headache, and diplopia. Since rufinamide is not metabolized by the CYP450 system, it is anticipated to have a low potential for interaction with drugs metabolized by the CYP isozymes. Rufinamide, however, does exhibit clinically relevant interactions with other antiepileptic drugs; concomitant treatment with valproate results in a reduction in rufinamide clearance while concomitant treatment with phenytoin, primidone, phenobarbital, carbamazepine, or vigabatrin causes an increase in rufinamide clearance. In these situations, rufinamide dosage adjustment may be required.
Rufinamide Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Jigs Chemical ltd | +919099003427 | Gujarat, India | 239 | 58 | Inquiry |
| Lupin Ltd | +91-8019896181 +91-8019896181 | Maharashtra, India | 93 | 58 | Inquiry |
| Glenmark Pharmaceuticals Limited | +912240189999 | Maharashtra, India | 93 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| AKASH PHARMA EXPORTS | +91-9388123451 +91-9846039283 | Kerela, India | 470 | 58 | Inquiry |
| Manus Aktteva Biopharma LLP | 08048250218Ext 800 | Ahmedabad, India | 655 | 58 | Inquiry |
| MSN LIFE SCIENCES PRIVATE LTD | +91 84523 34200 | New Delhi, India | 104 | 58 | Inquiry |
| MSN LABORATORIES PRIVATE LTD | +91 40 30438600 | New Delhi, India | 230 | 58 | Inquiry |
| GLENMARK LIFE SCIENCES LTD | +91 22 4018 9999 | New Delhi, India | 103 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Jigs Chemical ltd | 58 |
| Lupin Ltd | 58 |
| Glenmark Pharmaceuticals Limited | 58 |
| Hetero Drugs Limited | 58 |
| AKASH PHARMA EXPORTS | 58 |
| Manus Aktteva Biopharma LLP | 58 |
| MSN LIFE SCIENCES PRIVATE LTD | 58 |
| MSN LABORATORIES PRIVATE LTD | 58 |
| GLENMARK LIFE SCIENCES LTD | 58 |
| A.J Chemicals | 58 |
106308-44-5(Rufinamide)Related Search:
1of4
chevron_right